Search JTA's historical archive dating back to 1923

News Brief

May 4, 2000
See Original Daily Bulletin From This Date

A genetic mutation that predisposes Ashkenazi Jewish women to ovarian cancer makes them more responsive to chemotherapy, according to a new study. Patients with the BRCA mutation lived about two years longer than patients without the gene, according to the study of 189 Jewish women published in this week’s edition of the Journal of the American Medical Association.

Recommended from JTA